Hepatitis C in the rituximab era

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

Original languageEnglish (US)
Pages (from-to)5081-5082
Number of pages2
JournalBlood
Volume116
Issue number24
DOIs
StatePublished - Dec 9 2010
Externally publishedYes

Fingerprint

Chemotherapy
Hepatitis C
Viruses
Cells
Lymphoma, Large B-Cell, Diffuse
Virus Diseases
Hepacivirus
Multicenter Studies
R-CHOP protocol
Rituximab

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Hepatitis C in the rituximab era. / Foran, James M.

In: Blood, Vol. 116, No. 24, 09.12.2010, p. 5081-5082.

Research output: Contribution to journalArticle

Foran, James M. / Hepatitis C in the rituximab era. In: Blood. 2010 ; Vol. 116, No. 24. pp. 5081-5082.
@article{178842daa4664ece85107a95c8be6b27,
title = "Hepatitis C in the rituximab era",
abstract = "In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.",
author = "Foran, {James M}",
year = "2010",
month = "12",
day = "9",
doi = "10.1182/blood-2010-09-307827",
language = "English (US)",
volume = "116",
pages = "5081--5082",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Hepatitis C in the rituximab era

AU - Foran, James M

PY - 2010/12/9

Y1 - 2010/12/9

N2 - In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

AB - In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

UR - http://www.scopus.com/inward/record.url?scp=78650071123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650071123&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-09-307827

DO - 10.1182/blood-2010-09-307827

M3 - Article

VL - 116

SP - 5081

EP - 5082

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -